Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Shi, Weiwei, Zhang, Shan, Ma, Ding, Yan, Dongliang, Zhang, Guang, Cao, Yin, Wang, Zhongxia, Wu, Junhua, Jiang, Chunping
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327090/
https://ncbi.nlm.nih.gov/pubmed/32670862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00694
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados